SSW
CORT icon

Smith Shellnut Wilson’s Corcept Therapeutics CORT Stock Holding History

Smith Shellnut Wilson’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$419K Buy
+4,819
New +$291K 0.16% 94
2025
Q4 		– Sell
-4,819
Closed -$401K – 145
2025
Q3 		$401K Hold
4,819
– – 0.15% 90
2025
Q2 		$354K Hold
4,819
– – 0.15% 92
2025
Q1 		$550K Hold
4,819
– – 0.25% 67
2024
Q4 		$243K Hold
4,819
– – 0.11% 129
2024
Q3 		$223K Buy
+4,819
New +$171K 0.1% 137

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smith Shellnut Wilson's CORT Position: Q2 2026 in Review

Smith Shellnut Wilson opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 4,819 shares worth $419K. The stake represents 0.16% of the portfolio and ranks #94 among its holdings. This is a return to the name: Smith Shellnut Wilson previously reported a position in CORT as recently as Q3 2025.

Smith Shellnut Wilson first reported a position in CORT in Q3 2024 and has held it in 6 quarters since. The position peaked at $550K in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Smith Shellnut Wilson held 4,819 shares of Corcept Therapeutics worth $419K as of Q2 2026.
  • Corcept Therapeutics was a new Smith Shellnut Wilson position in Q2 2026.
  • Corcept Therapeutics made up 0.16% of Smith Shellnut Wilson's portfolio in Q2 2026, its #94 holding.
  • Smith Shellnut Wilson first reported a position in Corcept Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Smith Shellnut Wilson's Corcept Therapeutics position peaked at $550K in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Smith Shellnut Wilson's 13F filing for Q2 2026, filed 3 Aug 2026.